Back Article

  • Alexander D C. A rapid method for determining clone frequency in complex populations using PCR and the Poisson distribution[J]. Nucl Acids Res, 1990, 18(24): 7453-7454. doi: 10.1093/nar/18.24.7453

  • Bélec L, Piketty C, Si-Mohamed A. High levels of drug-resistant Human Immunodeficiency Virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy[J]. J Infect Dis, 2000, 181(5): 1808-1812. doi: 10.1086/jid.2000.181.issue-5

  • Chen Z, Li Y, Schock H B. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials[J]. J Biol Chem, 1995, 270(37): 21433-21436. doi: 10.1074/jbc.270.37.21433

  • Clavel F, Hance A J. HIV drug resistance[J]. N Engl J Med, 2004, 350(10): 1023-1035. doi: 10.1056/NEJMra025195

  • Coffin J M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy[J]. Science, 1995, 267(): 483-489. doi: 10.1126/science.7824947

  • Condra J H, Holder D J, Schleif W A. Genetic correlates of in vivo viral resistance to Indinavir, a Human Immunodeficiency Virus type 1 protease inhibitor[J]. J Virol, 1996, 70(12): 8270-8276.

  • Descamps D, Joly V, Flandre P. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073)[J]. J Clin Virol, 2005, 33(): 99-103. doi: 10.1016/j.jcv.2004.05.019

  • Dybul M, Daucher M, Jensen M A. Genetic characterization of rebounding Human Immunodeficiency Virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy[J]. J Virol, 2003, 77(5): 3229-3237. doi: 10.1128/JVI.77.5.3229-3237.2003

  • Gunthard H F, Wong J K, Ignacio C C. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples[J]. AIDS Res Hum Retroviruses, 1998, 14(): 869-876. doi: 10.1089/aid.1998.14.869

  • Kaplan A H, Michael S F, Wehbie R S. Selection of multiple Human Immunodeficiency Virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease[J]. Proc. Natd. Acad. Sci, 1994, 91(): 5597-5601. doi: 10.1073/pnas.91.12.5597

  • Kinai E, Hanabusa H, Kato S. Prediction of the efficacy of antiviral therapy for Hepatitis C Virus infection by an ultrasensitive RT-PCR assay[J]. J Med Virol, 2007, 79(): 1113-1119. doi: 10.1002/(ISSN)1096-9071

  • Kondo M, Sudo K, Tanaka R. Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR[J]. J Virol Methods, 2009, 157(): 141-146. doi: 10.1016/j.jviromet.2008.12.006

  • Mansky L M, Temin H M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase[J]. J Virol, 1995, 69(): 5087-5094.

  • Palmer S, Kearney M, Maldarelli F. Multiple, linked Human Immunodeficiency Virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis[J]. J Clin Microbiol, 2005, 43(1): 406-413. doi: 10.1128/JCM.43.1.406-413.2005

  • Perelson A S, Neumann A U, Markowitz M. HIV-1 dynamics in vivo: viron clearance rate, infected cell life-span, and viral generation time[J]. Science, 1996, 271(5255): 1582-1586. doi: 10.1126/science.271.5255.1582

  • Preston B D, Poiesz B J, Loeb L A. Fidelity of HIV-1 reverse transcriptase[J]. Science, 1988, 242(): 1168-1171. doi: 10.1126/science.2460924

  • Rhee S Y, Taylor J, Wadhera G. Genotypic predictors of human immunodeficiency virus type 1 drug resistance[J]. Proc Natl Acad Sci USA, 2006, 103(): 17355-17360. doi: 10.1073/pnas.0607274103

  • Ridky T W, Kikonyogo A, Leis J. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate[J]. Biochemistry, 1998, 37(39): 11835-11845.

  • Roberts J D, Bebenek K, Kunkel T A. The accuracy of reverse transcriptase from HIV-1[J]. Science, 1988, 242(): 1171-1173. doi: 10.1126/science.2460925

  • Rousseau C M, Birditt B A, McKay A R. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes[J]. J Virol Methods, 2006, 136(): 118-125. doi: 10.1016/j.jviromet.2006.04.009

  • Saah, Haas, DiNubile. Treatment with Indinavir, Efavirenz, and Adefovir after failure of Nelfinavir therapy[J]. J Infect Dis, 2003, 187(7): 1157-1162. doi: 10.1086/jid.2003.187.issue-7

  • Salazar-Gonzalez J F, Bailes E, Pham K T. Deciphering Human Immunodeficiency Virus type 1 transmission and early envelope diversification by single genome amplification and sequencing[J]. J Virol, 2008, 82(8): 3952-3970. doi: 10.1128/JVI.02660-07

  • Schuurman R, Brambilla D, Groot T D. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program[J]. AIDS Res Hum Retroviruses, 2002, 18(): 243-248. doi: 10.1089/088922202753472801

  • Simmonds P, Balfe P, Peutherer J F. Human Immunodeficiency Virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers[J]. J Virol, 1990, 64(2): 864-872.

  • Sykes P J, Neoh S H, Brisco M J. Quantitation of targets for PCR by use of limiting dilution[J]. Biotechniques, 1992, 13(3): 444-449.

  • Yap S H, Sheen C W, Fahey J. N348I in the connection domain of HIV-1 reverse transcriptase confers Zidovudine and Nevirapine resistance[J]. Plos Med, 2007, 4(12): 1887-1899.